Search results for "Coagulation"

showing 10 items of 381 documents

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

2017

The direct oral anticoagulants (DOACs) have been compared with parenteral anticoagulants and vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) in several robust studies. DOACs have shown similar efficacy in preventing recurrent VTE and significant reductions in critical site (intracranial) bleeding, fatal bleeding, major and nonmajor bleeding. Warfarin and other VKAs are not dead as treatment modalities for VTE. A better way to describe the current situation is to use a boxing expression, “down but not out.” VKAs and parenteral anticoagulants still have a role to play in the management of VTE in several clinical settings. In indications where DOACs can be used, …

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyAdministration OralClinical settingsVitamin kCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineSecondary PreventionmedicineHumanscardiovascular diseasesIntensive care medicineOral anticoagulationCerebral Hemorrhagebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismSafety profile030104 developmental biologyTreatment modalityvenous thromboembolism oral anticoagulation warfarin non-VKA oral anticoagulants safety efficacy030220 oncology & carcinogenesisWarfarinbusinessVenous thromboembolismmedicine.drug
researchProduct

Effects of different genotypes at the CSN3 and LGB loci on milk and cheese-making characteristics of the bovine Cinisara breed

2017

The Cinisara is an autochthonous Sicilian bovine breed reared mainly for production of Caciocavallo Palermitano, a typical stretched-curd cheese. The distribution of A and B alleles at both the β-lactoglobulin (LGB) and κ-casein (CSN3) loci in Cinisara cows and their influence on milk traits and cheese yield and composition were analysed. The LGB alleles are associated with significantly different effects on whey protein level (lower for BB genotype, P < 0.01), and casein index (higher value for BB genotype, P < 0.001), while CSN3 alleles were associated with significantly different effects on milk yield and coagulation properties; the BB genotype showed higher values for milk yield (…

0301 basic medicineSettore AGR/19 - Zootecnica SpecialeWhey proteink-caseincow milkCinisaraBeta-lactoglobulin0402 animal and dairy sciencefood and beveragesCheese yield04 agricultural and veterinary sciencesBiologyCoagulation propertie040201 dairy & animal scienceApplied Microbiology and BiotechnologyBreed03 medical and health sciences030104 developmental biologyMilk yieldCaseinCinisara; cow milk; k-casein; Beta-lactoglobulin; Coagulation properties; Cheese yields;GenotypeComposition (visual arts)Food scienceFood ScienceInternational Dairy Journal
researchProduct

Inflammation and the coagulation system in tuberculosis: Tissue Factor leads the dance

2016

Mycobacterium tuberculosis, the causative agent of tuberculosis, drives the formation of granulomas, structures in which both immune cells and the bacterial pathogen cohabit. The most abundant cells in granulomas are macrophages, which contribute as both cells with bactericidal activity and as targets for M. tuberculosis infection and proliferation during the entire course of infection. The mechanisms and factors involved in the regulation and control of macrophage microenvironment-specific polarization and plasticity are not well understood, as some granulomas are able to control bacteria growth and others fail to do so, permitting bacterial spread. In this issue of the European Journal of…

0301 basic medicineTuberculosisMacrophageTuberculosiImmunologyInflammationMacrophages; Mycobacterium tuberculosis; Tissue Factor; Tuberculosis; Animals; Bacteremia; Cell Differentiation; Fibrin; Host-Pathogen Interactions; Humans; Immunity Innate; Lung; Macrophages; Mice; Mice Knockout; Mycobacterium tuberculosis; Pneumonia; Thromboplastin; Tuberculoma; Tuberculosis Pulmonary; Blood Coagulation; Immunology; Immunology and Allergy; Medicine (all)BacteremiaMycobacterium tuberculosiThromboplastinMycobacterium tuberculosis03 medical and health sciencesTissue factorMiceImmune systemImmunitymedicineMacrophageImmunology and AllergyAnimalsHumansTuberculomaBlood CoagulationLungTuberculosis PulmonaryMice KnockoutFibrinCord factorbiologyAnimalMedicine (all)MacrophagesCell DifferentiationMycobacterium tuberculosisPneumoniabiology.organism_classificationmedicine.diseaseImmunity Innate3. Good healthTissue FactorHost-Pathogen Interaction030104 developmental biologyImmunologyHost-Pathogen Interactionsmedicine.symptomHumanEuropean Journal of Immunology
researchProduct

Thrombo-Inflammation in Cardiovascular Disease

2020

AbstractThrombo-inflammation describes the complex interplay between blood coagulation and inflammation that plays a critical role in cardiovascular diseases. The third Maastricht Consensus Conference on Thrombosis assembled basic, translational, and clinical scientists to discuss the origin and potential consequences of thrombo-inflammation in the etiology, diagnostics, and management of patients with cardiovascular disease, including myocardial infarction, stroke, and peripheral artery disease. This article presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following topics: (1) challenges of the endothelial cell barrier; (2) circulating …

0301 basic medicineVENOUS THROMBOSISmedicine.medical_specialtypulmonary embolismNeutrophilsIschemiaISCHEMIA-REPERFUSION INJURYDisease030204 cardiovascular system & hematologyCATHETER-DIRECTED THROMBOLYSIS03 medical and health sciences0302 clinical medicinePERIPHERAL ARTERY-DISEASEMedicineAnimalsHumansPlateletMyocardial infarctionDEEP-VEIN THROMBOSIScoagulationIntensive care medicineStrokeBlood CoagulationExpert Testimonythrombosisbusiness.industryACUTE CORONARY SYNDROMESNEUTROPHIL EXTRACELLULAR TRAPSHematologyNeutrophil extracellular trapsVenous ThromboembolismACTIVATABLE FIBRINOLYSIS INHIBITORmedicine.diseaseAtherosclerosisThrombosisstrokeImmunity Innate3. Good healthVenous thrombosis030104 developmental biologymyocardial infarctionTISSUE FACTORCardiovascular DiseasesinflammationplateletsEndothelium VascularbusinessSUBCLINICAL LEAFLET THROMBOSISThrombosis and Haemostasis
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Tissue factor prothrombotic activity is regulated by integrin-arf6 trafficking

2017

Objective— Coagulation initiation by tissue factor (TF) is regulated by cellular inhibitors, cell surface availability of procoagulant phosphatidylserine, and thiol-disulfide exchange. How these mechanisms contribute to keeping TF in a noncoagulant state and to generating prothrombotic TF remain incompletely understood. Approach and Results— Here, we study the activation of TF in primary macrophages by a combination of pharmacological, genetic, and biochemical approaches. We demonstrate that primed macrophages effectively control TF cell surface activity by receptor internalization. After cell injury, ATP signals through the purinergic receptor P2rx7 induce release of TF + microvesicles. T…

0301 basic medicinedynaminsIntegrin alpha4CellCardiorespiratory Medicine and Haematology030204 cardiovascular system & hematologyIntegrin alpha4beta1Inbred C57BLTransgenicMicechemistry.chemical_compound0302 clinical medicineAdenosine TriphosphateCell-Derived MicroparticlesReceptors2.1 Biological and endogenous factorsfibrinGene Knock-In TechniquesAetiologyPhospholipidsTumorbiologyChemistryADP-Ribosylation FactorsHematologyPhosphatidylserineCell biologyProtein Transportmedicine.anatomical_structurePhenotypeProteomeextracellular vesiclesCardiology and Cardiovascular MedicinePurinergic P2X7BiotechnologySignal TransductionGenotypeproteomeClinical SciencesIntegrinMice TransgenicFactor VIIaTransfectionExtracellular vesiclesFibrinArticleCell LineThromboplastin03 medical and health sciencesTissue factorCell Line TumormedicineAnimalsHumansBlood CoagulationMacrophagesThrombosisMice Inbred C57BL030104 developmental biologyCardiovascular System & HematologyADP-Ribosylation Factor 6biology.proteinReceptors Purinergic P2X7
researchProduct

A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies

2021

Therapeutic targeting of blood coagulation is a challenging task as it interferes with the delicate balance of pro- and anticoagulant activities. Anticoagulants are employed in millions of thrombophilic patients worldwide each year. The treatment and prevention of venous thromboembolism has changed drastically. Traditional vitamin K antagonists are being replaced by direct oral anticoagulants (DOACs), which selectively target coagulation factors Xa or IIa. However for a growing population with comorbidities satisfying therapeutic options are still lacking and the quest for novel therapeutics continues. Recently, targeting factors XI or XII have emerged as new therapeutic strategies. As thes…

0301 basic medicinemedicine.drug_classPopulationVitamin kBioinformaticsTherapeutic targeting03 medical and health sciences0302 clinical medicinemicroRNAHumansMedicinePharmacology (medical)educationFactor XIPharmacologyHemostasiseducation.field_of_studybusiness.industryAnticoagulantAnticoagulantsThrombosisMicroRNAs030104 developmental biologyCoagulation030220 oncology & carcinogenesisHemostasisbusinessVenous thromboembolismPharmacology & Therapeutics
researchProduct

Shortened Activated Partial Thromboplastin Time May Help in Diagnosing Hereditary and Acquired Angioedema

2016

<b><i>Objective:</i></b> To evaluate whether activated partial thromboplastin time (APTT) could be used in the laboratory diagnosis of hereditary or acquired angioedema (HAE or AAE) with and without C1 inhibitor (C1-INH) deficiency. <b><i>Methods:</i></b> In a prospective investigation, APTT and other coagulation parameters were determined in 149 adult patients with various types of angioedema and in 26 healthy participants (HP). <b><i>Results:</i></b> Mean APTT was significantly shortened in HAE-C1-INH type I (p < 0.0001) and type II (p = 0.0017) and in AAE-C1-INH (p < 0.0001) compared to the HP. APTT was shorten…

0301 basic medicinemedicine.medical_specialtyImmunologyAcquired angioedemaGastroenterologyC1-inhibitorDiagnosis Differential03 medical and health sciencesPredictive Value of TestsInternal medicinemedicineHumansImmunology and Allergyheterocyclic compoundsProspective StudiesAngioedemaProspective cohort studyBlood CoagulationBlood coagulation testAngioedemamedicine.diagnostic_testbiologybusiness.industryAngioedemas HereditaryComplement C4General Medicinerespiratory systembacterial infections and mycosesrespiratory tract diseases030104 developmental biologyCoagulationPredictive value of testsAnesthesiaImmunologybiology.proteinPartial Thromboplastin TimeBlood Coagulation Testsmedicine.symptombusinessComplement C1 Inhibitor ProteinBiomarkerscirculatory and respiratory physiologyPartial thromboplastin timeInternational Archives of Allergy and Immunology
researchProduct

2018

Patients with inflammatory bowel disease (IBD) are susceptible to thromboembolism. Interestingly, IBD occurs less frequently in patients with inherited bleeding disorders. Therefore, we analyzed whether F9-deficiency is protective against the onset of acute colitis in a genetic hemophilia B mouse model. In the 3.5% dextran sulfate sodium (DSS)-induced colitis model, F9-deficient mice were protected from body-weight loss and had a reduced disease activity score. We detected decreased colonic myeloperoxidase activity and decreased CXCL1 levels in DSS-treated F9-deficient mice compared with wild-type (WT) littermate controls, indicating decreased neutrophil infiltration. Remarkably, we identif…

0301 basic medicinemedicine.medical_specialtyLipopolysaccharideBiologyCoagulation Factor IXmedicine.diseaseIntestinal epitheliumInflammatory bowel diseaseGeneral Biochemistry Genetics and Molecular BiologyCXCL103 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineEndocrinologychemistryInternal medicinemedicine030211 gastroenterology & hepatologyColitisGeneral Agricultural and Biological SciencesReceptorAcute colitisBiology Open
researchProduct

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis

2018

AbstractAtherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagulation proteases, interacting with circulating cells and in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed with audience members and the results of these discussions were incorporated in the final document that presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following five topics: 1. Risk factors, biomarkers and plaque inst…

0301 basic medicinemedicine.medical_specialtyanticoagulantsADJUST ANTIPLATELET THERAPYPERCUTANEOUS CORONARY INTERVENTION030204 cardiovascular system & hematologyarterial thrombosisArticleantiplatelet therapyACTIVATED PROTEIN-CRED-BLOOD-CELLS03 medical and health sciences0302 clinical medicineVITAMIN-K ANTAGONISTSInternal medicineatherothrombosisIschaemic strokeNONVALVULAR ATRIAL-FIBRILLATIONmedicinePlateletatrial fibrillationACUTE ISCHEMIC-STROKEcoagulationATOMIC-FORCE MICROSCOPYCardiovascular mortalityischaemic strokeAtomic force microscopybusiness.industryConsensus conferenceHematologymedicine.diseaseThrombosis030104 developmental biologymyocardial infarctionCoagulationplateletsDIRECT ORAL ANTICOAGULANTSCardiologyPosition paperSYMPTOMATIC VENOUS THROMBOEMBOLISMatherosclerosisbusiness
researchProduct